Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription numbers for its key weight-loss drugs sparked concerns about its competitive standing against rival Novo Nordisk.
Data for the week ending April 17 showed that prescriptions for Lilly’s injectable weight-loss drug, Zepbound, decreased, while its competitor’s drug, Wegovy, saw an increase. More concerning for investors were the early numbers for Lilly’s newly launched oral obesity pill, Foundayo. In its second week, it secured 3,707 prescriptions, which significantly trailed the 18,410 prescriptions Novo Nordisk’s rival pill achieved in its second week.
The shares closed the day at $883.89, down 3.7% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
Eli Lilly’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 23 days ago when the stock gained 4.7% on the news that the FDA approved Foundayo (orforglipron), its highly anticipated once-daily oral weight loss pill.
Foundayo offers a needle-free alternative for obesity management without the strict fasting or water restrictions that hamper competing oral GLP-1s. Beyond the “weight-loss win,” investor confidence was boosted by Lilly’s $7.8 billion acquisition of Centessa Pharmaceuticals. This pivot into the neuroscience and sleep-wake disorder market demonstrates a proactive effort to diversify revenue and reduce long-term reliance on metabolic health.
Eli Lilly is down 18.2% since the beginning of the year, and at $883.89 per share, it is trading 20.4% below its 52-week high of $1,110 from November 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $4,721.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
